Lymphoma Microenvironment in DLBCL and PTCL-NOS: the Key to Uncovering Heterogeneity and the Potential for Stratification

Overview

Journal J Clin Exp Hematop

Specialties Hematology
Pathology

Date 2022 Sep 28

PMID 36171096

Authors

Kohta Miyawaki

Takeshi Sugio

Affiliations

Soon will be listed here.

Abstract

Diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) are the most common subtypes of mature B cell neoplasm and T/NK cell lymphoma, respectively. They share a commonality in that they are, by definition, highly heterogeneous populations. Recent studies are revealing more about the heterogeneity of these diseases, and at the same time, there is an active debate on how to stratify these heterogeneous diseases and make them useful in clinical practice. The various immune cells and non-cellular components surrounding lymphoma cells, i.e., the lymphoma microenvironment, have been the subject of intense research since the late 2000s, and much knowledge has been accumulated over the past decade. As a result, it has become clear that the lymphoma microenvironment, despite its paucity in tissues, significantly impacts the lymphoma pathogenesis and clinical behavior, such as its prognosis and response to therapy. In this article, we review the role of the lymphoma microenvironment in DLBCL and PTCL-NOS, with particular attention given to its impact on the prognosis and stratification.

Citing Articles

Prognostic stratification in DLBCL patients with aberrant MYC gene.

Li J, Shaw V, Parthasarathy A, Li Y, Amos C, Cheng C Br J Haematol. 2024; 205(5):1782-1793.

PMID: 39137931 PMC: 11568942. DOI: 10.1111/bjh.19699.

Prognostic relevance of tumor-infiltrating CD4 cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma.

Ikeda D, Oura M, Uehara A, Tabata R, Narita K, Takeuchi M Haematologica. 2024; 109(9):2822-2832.

PMID: 38572548 PMC: 11367203. DOI: 10.3324/haematol.2024.285038.

Targeting the cGAS-STING Pathway Inhibits Peripheral T-cell Lymphoma Progression and Enhances the Chemotherapeutic Efficacy.

Lu X, Wang S, Hua X, Chen X, Zhan M, Hu Q Adv Sci (Weinh). 2023; 11(10):e2306092.

PMID: 38145335 PMC: 10933671. DOI: 10.1002/advs.202306092.

Robust deep learning-based PET prognostic imaging biomarker for DLBCL patients: a multicenter study.

Jiang C, Qian C, Jiang Z, Teng Y, Lai R, Sun Y Eur J Nucl Med Mol Imaging. 2023; 50(13):3949-3960.

PMID: 37606859 DOI: 10.1007/s00259-023-06405-y.

Comparison of serum sIL-2R and LDH levels in patients with intravascular large B-cell lymphoma and patients with advanced stage diffuse large B-cell lymphoma.

Hirami Y, Nishimura M, Urata T, Morimoto M, Maekawa Y, Yoshino T J Clin Exp Hematop. 2023; 63(1):25-31.

PMID: 36843068 PMC: 10158718. DOI: 10.3960/jslrt.22043.

References

Iqbal J, Weisenburger D, Greiner T, Vose J, McKeithan T, Kucuk C . Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2009; 115(5):1026-36. PMC: 2817630. DOI: 10.1182/blood-2009-06-227579. View

Singh R, Kunkalla K, Qu C, Schlette E, Neelapu S, Samaniego F . ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene. 2011; 30(49):4874-86. PMC: 3165099. DOI: 10.1038/onc.2011.195. View

Cai Q, Liao H, Lin S, Xia Y, Wang X, Gao Y . High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol. 2011; 29(4):2317-22. DOI: 10.1007/s12032-011-0123-6. View

McCord R, Bolen C, Koeppen H, Kadel 3rd E, Oestergaard M, Nielsen T . PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019; 3(4):531-540. PMC: 6391660. DOI: 10.1182/bloodadvances.2018020602. View

Timmins M, Wagner S, AHearne M . The new biology of PTCL-NOS and AITL: current status and future clinical impact. Br J Haematol. 2020; 189(1):54-66. DOI: 10.1111/bjh.16428. View

Brandt S, Montagna C, Georgis A, Schuffler P, Buhler M, Seifert B . The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma. Exp Hematol Oncol. 2014; 2(1):27. PMC: 3852975. DOI: 10.1186/2162-3619-2-27. View

Baumann I, Kolowos W, Voll R, Manger B, Gaipl U, Neuhuber W . Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 2002; 46(1):191-201. DOI: 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K. View

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

10.

Green M . Chromatin modifying gene mutations in follicular lymphoma. Blood. 2017; 131(6):595-604. PMC: 5805487. DOI: 10.1182/blood-2017-08-737361. View

11.

Drieux F, Ruminy P, Abdel-Sater A, Lemonnier F, Viailly P, Fataccioli V . Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay. Haematologica. 2019; 105(6):1582-1592. PMC: 7271600. DOI: 10.3324/haematol.2019.226647. View

12.

Coutinho R, Clear A, Mazzola E, Owen A, Greaves P, Wilson A . Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica. 2014; 100(3):363-9. PMC: 4349275. DOI: 10.3324/haematol.2014.110189. View

13.

Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A . Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol. 2012; 31(2):256-62. PMC: 5321049. DOI: 10.1200/JCO.2011.39.9881. View

14.

Northcott P, Shih D, Remke M, Cho Y, Kool M, Hawkins C . Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2011; 123(4):615-26. PMC: 3306784. DOI: 10.1007/s00401-011-0899-7. View

15.

Rodriguez-Pinilla S, Atienza L, Murillo C, Perez-Rodriguez A, Montes-Moreno S, Roncador G . Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol. 2008; 32(12):1787-99. DOI: 10.1097/PAS.0b013e31817f123e. View

16.

Xu Y, Kroft S, McKenna R, Aquino D . Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J Haematol. 2001; 112(4):945-9. DOI: 10.1046/j.1365-2141.2001.02649.x. View

17.

Sugio T, Miyawaki K, Kato K, Sasaki K, Yamada K, Iqbal J . Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv. 2018; 2(17):2242-2252. PMC: 6134219. DOI: 10.1182/bloodadvances.2018018754. View

18.

Pescarmona R, Belot A, Villard M, Besson L, Lopez J, Mosnier I . Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies. Cytokine. 2018; 113:446-452. DOI: 10.1016/j.cyto.2018.10.023. View

19.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

20.

Krishnan C, Warnke R, Arber D, Natkunam Y . PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. Am J Surg Pathol. 2010; 34(2):178-89. PMC: 2819320. DOI: 10.1097/PAS.0b013e3181cc7e79. View